PURETECH HEALTH PLC LS 1

Research PURETECH HEALTH PLC LS 1 (0VQ) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker0VQ
• ExchangeF
• CountryUnited States
• CurrencyEUR
• Financial periodFY2025
• RevenueUSD 4.66M
• Revenue growth-3.5%
• Net income-USD 110.08M
• Free cash flow-USD 85.14M

About PURETECH HEALTH PLC LS 1

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.

Frequently asked questions

What does PURETECH HEALTH PLC LS 1 do?

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.